Status:
RECRUITING
Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)
Lead Sponsor:
Institut de Cancérologie de Lorraine
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.
Eligibility Criteria
Inclusion
- locally advanced, operable melanoma
- treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.
Exclusion
- second cancer
- woman who is pregnant, likely to be pregnant or breastfeeding
Key Trial Info
Start Date :
January 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT04866680
Start Date
January 31 2023
End Date
October 1 2029
Last Update
May 16 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Jean Minjoz
Besançon, France
2
CGFL
Dijon, France
3
Chu Dijon
Dijon, France
4
Chru Lille
Lille, France